Related Experiment Video

Updated: Jun 24, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II

Anne M Traynor1, Sarita Dubey, Jens C Eickhoff

  • 1University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 7, 2009
PubMed
Abstract

Insights

Single-agent vorinostat did not show antitumor activity in relapsed non-small cell lung cancer (NSCLC). However, it demonstrated a time to progression (TTP) comparable to other targeted therapies, suggesting potential in combination treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Vorinostat is a histone deacetylase inhibitor with preclinical activity in non-small cell lung cancer (NSCLC).
  • Investigating novel therapeutic agents is crucial for improving outcomes in relapsed NSCLC.

Purpose of the Study:

  • To evaluate the efficacy and safety of single-agent vorinostat in patients with relapsed NSCLC.
  • To determine the response rate, time to progression (TTP), and overall survival (OS) of vorinostat treatment.

Main Methods:

  • A two-stage minimax design was used to assess response rate in 14 evaluable patients with relapsed NSCLC.
  • Patients received oral vorinostat at 400 mg daily.
  • Secondary endpoints included TTP, OS, and safety assessments.

Main Results:

  • No objective antitumor responses were observed in the 14 evaluable patients.
  • Eight patients achieved stable disease, with a median duration of 3.7 months.
  • Median TTP was 2.3 months, median OS was 7.1 months, and the 1-year OS rate was 19%.
  • Grade 3/4 adverse events possibly related to vorinostat included neutropenia, fatigue, and pulmonary embolism.

Conclusions:

  • Single-agent vorinostat did not demonstrate objective antitumor activity in relapsed NSCLC.
  • Vorinostat showed a TTP similar to other targeted agents in this patient population.
  • Future NSCLC research should explore combinations of vorinostat with other antitumor agents.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...